彭华研究员
研究简介
长期从事病毒与免疫学研究，专注于机体抗病毒感染免疫应答机制研究、病毒相关肿瘤的免疫治疗药物研究、以及抗病毒的预防/治疗性疫苗平台建设，取得重要的系统性的科研与转化成果。近五年以通讯作者发表20余篇高水平研究论文，分别发表在Nat BioMed Eng, JEM, J Clin Invest, Gut, Cell Res, Cell Discov, Sci Immuno, Gastro, Nat Commun等学术期刊。彭华团队研发了完全自主知识产权的创新型新冠病毒融合蛋白疫苗，并与丽珠生物联合开发新冠疫苗产品（丽康V-01）。该疫苗已于2022年6月获国家批准作为加强针纳入紧急使用，并于2022年9月正式纳入新冠疫苗免疫规划系统。针对新冠变异株的丽珠二价疫苗BV-01-QX于2023年12月又一次获批紧急使用，为后续加强免疫规划接种实施方案提供更优选择。
荣誉奖励
1. 广州市重大人才项目领军人才
2. 黄埔区重大人才计划精英人才
代表性成果
1. Lin Y#, Liao X#, Cao X#, Zhang Z#, Wang X, He X, Liao H, Ju B, Qi F, Xu H, Ren Z, Wang Y, Fu Y-X*, Zhao J*, Zhang Z*, and Peng H*. Sequential intranasal booster triggers class switching from intramuscular primed IgG to mucosal IgA against SARS-CoV-2. J Clin Invest. 2025 Jan 14;135(5):e175233.
2. Cai Y#, Han Z#, Shen J, Zou Z, Guo J, Liang Y, Li S, Liao H, Ren Z, Peng H*, Fu YX*. Concurrent intratumoural Treg cell depletion and CD8+ T cell expansion via a cleavable anti-4-1BB-interleukin-15 fusion protein. Nat Biomed Eng. 2025 Jun;9(6):952-966.
3. Zou Z#, Shen J. #, Xue D, Li H, Xu L, Cao W, Wang W, Fu YX*, Peng H.*. Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8+T cells for systemic antitumor responses. Nat Commun. 2024 Jun 3;15(1):4701.
4. Chao-Yang Meng, Shiyu Sun, Yong Liang, Hairong Xu, Chao Zhang, Min Zhang, Fu-Sheng Wang, Yang-Xin Fu*, Hua Peng*. Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance. Gut. 2023 Aug;72(8):1544-1554.
5. Shen J#, Zou Z#, Guo J, Cai Y, Xue D, Liang Y, Wang W, Peng H*, Fu YX*. An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery. J Exp Med. 2022 Dec 5;219(12): e20220745.
6. Yifan Lin#, Jing Sun#, Xuezhi Cao#, Xiuye Wang, Xi Chen, Hairong Xu, Jincun Zhao*, Yang-Xin Fu* and Hua Peng*. Non-adjuvanted interferon-armed RBD protein nasal drops protect airway infection from SARS-CoV-2. Cell Discov. 2022; 8: 43.
7. Diyuan Xue#, Benjamin Moon#, Jing Liao, Jingya Guo, Zhuangzhi Zou, Yanfei Han, Shuaishuai Cao, Yang Wang, Yang-Xin Fu*, Hua Peng*. A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors. Science Immunology, 2022 Jan 7;7(67):eabi6899
8. Shiyu Sun#, Xi Chen#, Jingjing Lin, Junwen Ai, Jiaming Yang, Zhenxiang Hu, Yang-Xin Fu*, Hua Peng*. Broad neutralization against SARS-CoV-2 variants induced by a next-generation protein vaccine V-01. Cell Discov. 2021 Nov 30;7(1):114.
9. Sunshiyu Sun#, Yueqi Cai#, Tian-Zhang Song#, Yang Pu#, Lin Cheng, Hairong Xu, Chaoyang Meng Yifan Lin, Haibin Huang, Fang Zhao, Jing Sun, Silin Zhang, Yu Gao, Jian-Bao Han, Xiao-Li Feng, Dan-Dan Yu, Haidong Tang, Jincun Zhao, Zheng Zhang, Jiaming Yang, Zhenxiang Hu, Yang-Xin Fu*, Yong-Tang Zheng*, Hua Peng*. Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. Cell Res. 2021 Sep;31(9):1011-1023.
10. Jingya Guo, Yong Liang, Diyuan Xue, Jiao Shen, Yueqi Cai, Jiankun Zhu, Yang-Xin Fu*, Hua Peng*. Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity. Cell Res. 2021 Nov;31(11):1190-1198.
长期从事病毒与免疫学研究，专注于机体抗病毒感染免疫应答机制研究、病毒相关肿瘤的免疫治疗药物研究、以及抗病毒的预防/治疗性疫苗平台建设，取得重要的系统性的科研与转化成果。近五年以通讯作者发表20余篇高水平研究论文，分别发表在Nat BioMed Eng, JEM, J Clin Invest, Gut, Cell Res, Cell Discov, Sci Immuno, Gastro, Nat Commun等学术期刊。彭华团队研发了完全自主知识产权的创新型新冠病毒融合蛋白疫苗，并与丽珠生物联合开发新冠疫苗产品（丽康V-01）。该疫苗已于2022年6月获国家批准作为加强针纳入紧急使用，并于2022年9月正式纳入新冠疫苗免疫规划系统。针对新冠变异株的丽珠二价疫苗BV-01-QX于2023年12月又一次获批紧急使用，为后续加强免疫规划接种实施方案提供更优选择。
荣誉奖励
1. 广州市重大人才项目领军人才
2. 黄埔区重大人才计划精英人才
代表性成果
1. Lin Y#, Liao X#, Cao X#, Zhang Z#, Wang X, He X, Liao H, Ju B, Qi F, Xu H, Ren Z, Wang Y, Fu Y-X*, Zhao J*, Zhang Z*, and Peng H*. Sequential intranasal booster triggers class switching from intramuscular primed IgG to mucosal IgA against SARS-CoV-2. J Clin Invest. 2025 Jan 14;135(5):e175233.
2. Cai Y#, Han Z#, Shen J, Zou Z, Guo J, Liang Y, Li S, Liao H, Ren Z, Peng H*, Fu YX*. Concurrent intratumoural Treg cell depletion and CD8+ T cell expansion via a cleavable anti-4-1BB-interleukin-15 fusion protein. Nat Biomed Eng. 2025 Jun;9(6):952-966.
3. Zou Z#, Shen J. #, Xue D, Li H, Xu L, Cao W, Wang W, Fu YX*, Peng H.*. Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8+T cells for systemic antitumor responses. Nat Commun. 2024 Jun 3;15(1):4701.
4. Chao-Yang Meng, Shiyu Sun, Yong Liang, Hairong Xu, Chao Zhang, Min Zhang, Fu-Sheng Wang, Yang-Xin Fu*, Hua Peng*. Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance. Gut. 2023 Aug;72(8):1544-1554.
5. Shen J#, Zou Z#, Guo J, Cai Y, Xue D, Liang Y, Wang W, Peng H*, Fu YX*. An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery. J Exp Med. 2022 Dec 5;219(12): e20220745.
6. Yifan Lin#, Jing Sun#, Xuezhi Cao#, Xiuye Wang, Xi Chen, Hairong Xu, Jincun Zhao*, Yang-Xin Fu* and Hua Peng*. Non-adjuvanted interferon-armed RBD protein nasal drops protect airway infection from SARS-CoV-2. Cell Discov. 2022; 8: 43.
7. Diyuan Xue#, Benjamin Moon#, Jing Liao, Jingya Guo, Zhuangzhi Zou, Yanfei Han, Shuaishuai Cao, Yang Wang, Yang-Xin Fu*, Hua Peng*. A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors. Science Immunology, 2022 Jan 7;7(67):eabi6899
8. Shiyu Sun#, Xi Chen#, Jingjing Lin, Junwen Ai, Jiaming Yang, Zhenxiang Hu, Yang-Xin Fu*, Hua Peng*. Broad neutralization against SARS-CoV-2 variants induced by a next-generation protein vaccine V-01. Cell Discov. 2021 Nov 30;7(1):114.
9. Sunshiyu Sun#, Yueqi Cai#, Tian-Zhang Song#, Yang Pu#, Lin Cheng, Hairong Xu, Chaoyang Meng Yifan Lin, Haibin Huang, Fang Zhao, Jing Sun, Silin Zhang, Yu Gao, Jian-Bao Han, Xiao-Li Feng, Dan-Dan Yu, Haidong Tang, Jincun Zhao, Zheng Zhang, Jiaming Yang, Zhenxiang Hu, Yang-Xin Fu*, Yong-Tang Zheng*, Hua Peng*. Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. Cell Res. 2021 Sep;31(9):1011-1023.
10. Jingya Guo, Yong Liang, Diyuan Xue, Jiao Shen, Yueqi Cai, Jiankun Zhu, Yang-Xin Fu*, Hua Peng*. Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity. Cell Res. 2021 Nov;31(11):1190-1198.